Approved on September 4, 2020, pralsetinib (Gavreto) represents a significant advancement in targeted cancer therapy.

Approved on September 3, 2020, Detectnet (copper Cu 64 dotatate) provides a critical tool for the diagnosis and management of NETs.

Approved on August 28, 2020, somapacitan (Sogroya) offers a convenient once-weekly injection, improving adherence and quality of life for patients.

Approved on August 26, 2020, clascoterone (Winlevi) offers a novel mechanism of action by inhibiting androgen receptors in the skin, reducing oil production and inflammation associated with acne.

Approved on August 7, 2020, oliceridine (Olinvyk) is intended for patients who have not found relief with other treatments.

risdiplam FDA approval on August 7, 2020, has provided new hope and convenience for individuals affected by SMA.

tafasitamab FDA approval on July 31, 2020, provides hope for patients with limited treatment options, though ongoing studies are necessary to fully understand its long-term efficacy and safety.

Approved by the FDA on July 24, 2020, it utilizes innovative CAR-T cell technology to target and eliminate cancer cells, although it comes with significant risks and side effects that require careful management by healthcare professionals.

on August 12, 2021, the FDA expanded its approval to include the treatment of idiopathic hypersomnia (IH) in adults.

The U.S. Food and Drug Administration (FDA) approved Inqovi on July 7, 2020, for the treatment of certain types of myelodysplastic syndromes (MDS).

The U.S. Food and Drug Administration (FDA) approved Rukobia on July 2, 2020, for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

The U.S. Food and Drug Administration (FDA) approved Dojolvi on June 30, 2020, for the treatment of long-chain fatty acid oxidation disorders (LC-FAODs) in adults and children.